-The Economic Times It is not malaria or TB that will be the cause of large number of deaths in the world, Cancer is on its way to become one the deadliest diseases in the coming decades, according to a research paper published in medical journal Lancet. The study lead by Dr Freddy Bay of International Agency for Research on Cancer, France,predicts that the number of Cancer patients in the world is...

A 26-year-old man from Hooghly who lost his tongue to cancer in a Mumbai hospital last week has lent his voice to a public health campaign urging the Bengal government to ban the sale of gutka laced with tobacco. Mantu Mahato, who was diagnosed with advanced tongue cancer earlier this year, five years after he started chewing gutka, has written a letter to chief minister Mamata Banerjee urging her to ban...

It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever compulsory licence in India for the manufacture of a drug still under patent....

India has achieved a major victory at the just concluded 65th World Health Assembly as it managed to push through a resolution on mental health, asking member-states to acknowledge the need for a comprehensive, coordinated response to addressing mental disorders from health and social sectors at the country level. The delegates recognised these measures which include programmes to reduce stigma and discrimination, reintegration of patients into workplace and society, support...

German drugmaker Bayer AG has demanded the withdrawal of the country's first compulsory licence given to Natco Pharma, arguing that a three-fourth reduction in the price of the anti-cancer drug by another Indian firm has made the permit redundant and its patent itself is vulnerable to being revoked. In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original...